144 related articles for article (PubMed ID: 10194038)
21. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
22. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.
Reggiani P; Arru M; Regazzi M; Gatti S; Molinaro MD; Caccamo L; Maggi U; Melada E; Paone G; Rossi G
Transplant Proc; 2005 May; 37(4):1697-9. PubMed ID: 15919435
[TBL] [Abstract][Full Text] [Related]
23. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
Kuypers DR; Vanrenterghem Y; Squifflet JP; Mourad M; Abramowicz D; Oellerich M; Armstrong V; Shipkova M; Daems J
Ther Drug Monit; 2003 Oct; 25(5):609-22. PubMed ID: 14508385
[TBL] [Abstract][Full Text] [Related]
24. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
25. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
[TBL] [Abstract][Full Text] [Related]
26. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
27. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses.
Kamar N; Marquet P; Gandia P; Muscari F; Lavayssière L; Esposito L; Guitard J; Canivet C; Peron JM; Alric L; Suc B; Saint-Marcoux F; Rostaing L
Ther Drug Monit; 2009 Aug; 31(4):451-6. PubMed ID: 19531983
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
[TBL] [Abstract][Full Text] [Related]
30. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.
Jain A; Sharma R; Ryan C; Tsoulfas G; Orloff M; Abt P; Kashyap R; Batzold P; Sauberman L; Safadjou S; Graham M; Bozorgzadeh A
Liver Transpl; 2008 Feb; 14(2):202-9. PubMed ID: 18236395
[TBL] [Abstract][Full Text] [Related]
31. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
32. Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.
Kim H; Yi NJ; Lee J; Kim J; Moon MR; Jeong J; Lee JM; You TS; Suh SW; Park MS; Choi Y; Hong G; Lee HW; Lee KW; Suh KS
Clin Mol Hepatol; 2014 Sep; 20(3):291-9. PubMed ID: 25320733
[TBL] [Abstract][Full Text] [Related]
33. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
35. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
[TBL] [Abstract][Full Text] [Related]
36. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
37. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report.
Shapiro R; Jordan ML; Scantlebury VP; Vivas C; Gritsch HA; Casavilla FA; McCauley J; Johnston JR; Randhawa P; Irish W; Hakala TR; Fung JJ; Starzl TE
J Urol; 1998 Dec; 160(6 Pt 1):1982-5; discussion 1985-6. PubMed ID: 9817305
[TBL] [Abstract][Full Text] [Related]
38. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts.
Filler G; Lampe D; Mai I; Strehlau J; Ehrich JH
Transpl Int; 1998; 11 Suppl 1():S82-5. PubMed ID: 9664950
[TBL] [Abstract][Full Text] [Related]
39. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation.
Jain A; Mohanka R; Orloff M; Abt P; Kashyap R; Kelley M; Burlee K; Bozorgzadeh A
Exp Clin Transplant; 2005 Dec; 3(2):361-5. PubMed ID: 16417444
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant.
Walker R; Thomas M; Goodman D; Campbell S; Chadban S;
Clin Transplant; 2008; 22(5):594-602. PubMed ID: 18459999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
